Autoinjectors Market

1. Autoinjectors Market The global autoinjectors market is anticipated to grow at a CAGR of 16.9% during the forecast period with its market size reaching USD 4.5 billion by 2024. Due to the prevalence of chronic and lifestyle-related diseases, the increasing incidence of anaphylaxis, and the development in technology, the market is rising at a considerable pace. Due to the benefits of disposable autoinjectors, such as handiness, less likelihood of contamination, and ease of use, the industry has seen a strong demand for disposable autoinjectors in the coming years. By Product, the autoinjector market is categorized into prefilled and fillable injectors. Prefilled injectors hold the larger share in the market and it is predicted that the product category will also grow at a faster rate during the forecast period. By design, the market is categorized into standardized and customized injectors. Standardized design of injectors is the majorly sold category, whereas the market for customized design injectors will witness the higher growth during the forecast period. By type, the market is subdivided into disposable and reusable autoinjectors. The disposable segment is expected to grow at a faster rate during the forecast period in the market. By therapy, the market is subdivided multiple sclerosis, anaphylaxis, rheumatoid arthritis, diabetes and others. Rheumatoid arthritis segment is expected to grow at the fastest rate in the market due increasing occurrence of rheumatoid arthritis, globally. The key growth factors for the market of autoinjectors are the growing prevalence of chronic and lifestyle-related illnesses, increasing number of regulatory approvals, technology improvement and design development, increasing medical attention and patient propensity to self-administration, mounting self-medication practise, and promising reimbursements and government support.

2. The growth of the market for autoinjectors is also facilitated by the patent expiry of biologics, novel formulations and revolutionary drug delivery systems, coupled with the discovery and improvement of biological drugs, increased healthcare spending, increased incidence of anaphylaxis and accessibility of generic varieties of autoinjectors. Recent News: In December 2016, Mylan N.V. launched the authorized generic for EpiPen, as an autoinjector. Competitive Insights: Abbvie, Ypsomed, Consort Medical, Johnson & Johnson, Mylan, Becton, Dickinson and Company, Amgen, Haselmeier, ELI Lilly, Owen Mumford, Scandinavian Health Limited and Antares Pharma are the key players offering autoinjectors. VynZ Research Call: +91-996-028-8381 Toll-Free (U.S. and Canada): +1-888-253-3960 Email: enquiry@vynzresearch.com Web: https://www.vynzresearch.com Connect with Us:LinkedIn | Facebook | Twitter